Physician profile
Luis R Arencibia
NPI 1528266509
$1,271.63
in general payments reported to CMS, 2019-2025
11 companies · $252 in 2025
The $252 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $99.95 · 2021: $25.40 · 2022: $253 · 2023: $180 · 2024: $300 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $632 · Education: $99.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $632.31 |
| Education | $99.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $315.47 | 2019-2023 | Ofev |
| Kerecis Limited | $267.42 | 2019-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Hartmann USA, INC. | $158.48 | 2022-2023 | Zetuvit Plus |
| Mimedx Group, INC. | $130.87 | 2024 | |
| Solventum Corporation | $127.61 | 2025 | Silvercel, 3m Coban, Promogran Prisma |
| Teva Pharmaceuticals USA, INC. | $99.50 | 2025 | |
| Kci USA, INC. | $57.89 | 2020 | |
| Organogenesis INC. | $47.96 | 2019 | |
| Ucb, INC. | $26.36 | 2024 | Briviact |
| Neurocrine Biosciences, INC. | $24.53 | 2025 | |
| Paratek Pharmaceuticals, INC. | $15.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Arencibia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.